Xencor Inc (XNCR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.78B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xencor Inc (XNCR) Competitors
The companies most similar to Xencor are Xenon Pharmaceuticals (XENE), Celldex Therapeutics (CLDX) and Zenas BioPharma, Inc. Common Stock (ZBIO). By market cap, Xencor ranks 7th of the 13 companies on this page; Xenon Pharmaceuticals (XENE) is the largest at $3.98B. The median P/E of the 3 companies with a P/E is 89.8x.
Peer Comparison
XNCR's ROIC of -17.3% is above the peer median of -65.4%, and its revenue growth of 454.9% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Xencor (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Xenon Pharmaceuticals Inc (XENE) | $3.98B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Celldex Therapeutics Inc (CLDX) | $2.26B | N/A | N/A | 0.0% | N/A | -97.0% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| MBX Biosciences, Inc. Common Stock (MBX) | $2.78B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Celcuity LLC (CELC) | $3.15B | N/A | N/A | 0.0% | -25.2% | 0.0% | 0.00% |
| Vericel Corp Ord (VCEL) | $2.91B | 89.8x | 9.1x | 10.3% | N/A | 26.5% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Iovance Biotherapeutics Inc (IOVA) | $3.59B | N/A | 9.1x | -58.2% | N/A | 80.1% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Replimune Group Inc (REPL) | $2.08B | N/A | N/A | 0.0% | -65.4% | 0.0% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $3.14B | N/A | 5.3x | 3.8% | -0.7% | 22.3% | 0.00% |
| Arcus Biosciences Inc (RCUS) | $2.51B | N/A | 21.5x | 0.0% | -75.9% | -65.4% | 0.00% |
| Peer median | $2.84B | 89.8x | 9.1x | 0.0% | -65.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Xencor, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Xenon Pharmaceuticals Inc (XENE) | Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders... | XENE competitors |
| Celldex Therapeutics Inc (CLDX) | Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment... | CLDX competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| MBX Biosciences, Inc. Common Stock (MBX) | MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment... | MBX competitors |
| Celcuity LLC (CELC) | Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. | CELC competitors |
| Vericel Corp Ord (VCEL) | Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures... | VCEL competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Iovance Biotherapeutics Inc (IOVA) | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness... | IOVA competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Replimune Group Inc (REPL) | Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts. | REPL competitors |
| Telix Pharmaceuticals Limited (TLX) | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic... | |
| Arcus Biosciences Inc (RCUS) | Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. | RCUS competitors |
Frequently Asked Questions About XNCR
Who are Xencor's main competitors?
The companies most similar to Xencor include Xenon Pharmaceuticals (XENE), Celldex Therapeutics (CLDX), Zenas BioPharma, Inc. Common Stock (ZBIO), MBX Biosciences, Inc. Common Stock (MBX) and Celcuity LLC (CELC), listed from the closest match.
Who is Xencor's biggest competitor?
Xenon Pharmaceuticals (XENE) is both the largest of the similar companies at $3.98B and the closest match by business profile, size, sector and industry.
How does XNCR stock compare with its competitors?
XNCR's P/S is 13.5x against a peer median of 9.1x; its net margin is -58.8% against a peer median of 0.0%.
Which of Xencor's competitors pays a higher dividend?
Xencor pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Xencor bigger than its competitors?
No. Xencor is 7th by market cap among the 13 companies on this page; the largest is Xenon Pharmaceuticals (XENE) at $3.98B.
XNCR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors